HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

TNP 351

a novel antifolate being evaluated for chemotherapy of lung cancer

Also Known As:

N-(4-(3-(2,4-diamino-7H-pyrrolo(2,3-d)pyrimidin-5-yl)propyl)benzoyl)glutamic acid; TNP-351

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Pteridines: 147
      - Pterins: 160
        Aminopterin: 248
        Methotrexate: 24010
        TNP 351: 3

Related Diseases

1.	Neoplasms (Cancer) 02/01/1995 - "The clinical phase I study of TNP-351, an antifolate drug having a novel structure, was performed through a multicenter cooperative program in 40 patients with solid tumors. "
2.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/01/1994 - "The mechanism of action of TNP-351 was evaluated using some methotrexate-resistant CCRF-CEM human lymphoblastic leukemia cell lines as well as partially purified enzymes folylpolyglutamate synthetase (FPGS), aminoimidazolecarboxamide ribonucleotide transformylase (AICARTFase), and glycinamide ribonucleotide transformylase (GARTFase) from parent CCRF-CEM cells. "
3.	Lung Neoplasms (Lung Cancer) 01/01/1993 - "Among these antifolates, both edatrexate and trimetrexate have showed responses against lung cancer and we expect that TNP-351 may also show a similar response in the future. "

Related Drugs and Biologics

1.	Folic Acid Antagonists
2.	Phosphoribosylaminoimidazolecarboxamide Formyltransferase
3.	Phosphoribosylglycinamide Formyltransferase
4.	Trimetrexate (JB11)
5.	Methotrexate (Mexate)
6.	Enzymes
7.	edatrexate
8.	folylpolyglutamate synthetase